Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer...

Area of Science:

• Immunology
• Oncology
• Structural Biology

Background:

• Genetic mutations produce mutated proteins, yielding peptides presented as cancer neoantigens to T cells.
• T cells targeting neoantigens are crucial for effective cancer immunotherapies.
• Current neoantigen prediction algorithms identify only a minority of immunogenic neoantigens, with factors influencing immunogenicity not fully understood.

Purpose of the Study:

• To classify human neoantigen/neopeptide data based on T cell receptor-peptide-MHC binding events.
• To identify factors governing neoantigen immunogenicity.
• To improve neoantigen prioritization for enhanced cancer immunotherapy design.

Main Methods:

• Classification of human neoantigen/neopeptide data into three categories based on TCR-pMHC binding.
• Observation and definition of the 'NP' rule based on conservative mutant orientation of anchor residues in immunogenic neoantigens.
• Integration of the 'NP' rule with existing prediction algorithms and solving neoantigen/MHC structures.

Main Results:

• A conserved 'NP' rule was identified for immunogenic neoantigens.
• Integration of the 'NP' rule improved neoantigen prioritization performance.
• Structural analysis revealed that neoantigens following the 'NP' rule enhance peptide-MHC binding affinity and create novel TCR-binding features.

Conclusions:

• The 'NP' rule offers a valuable immune-based classification for neoantigen studies.
• Understanding neoantigen immunogenicity through structural insights can guide the design of more effective cancer immunotherapies.
• This research provides a foundation for developing improved strategies in cancer immunotherapy.